en Clinical Medicine Clinical Medicine مقاله پژوهشی Original Research Article <p style="text-align: justify;"><span style="font-size:16px;"><span style="font-family:Times New Roman;"><span style="color:#ffffff;"><strong><span style="background-color:#008080;">&nbsp;Background and Objective:</span></strong></span> The clinical outcomes and treatment options for acute myeloid leukemia (AML) patients are highly dependent upon molecular markers. In this study, Wilms tumor (WT1) (exons 7 and 9) mutations, SNP rs16754, and WT1 expression levels in 130 random AML patients were screened; FMs-like tyrosine kinase-3 internal tandem duplication (<em>FLT3-ITD</em>), nucleophosmin (<em>NPM1</em>), and CCAAT/enhancer-binding protein alpha (CEBPA) mutations were also evaluated.<br> <span style="color:#ffffff;"><strong><span style="background-color:#008080;">&nbsp;Material and Methods:</span></strong></span> Overall, 130 AML patients were recruited for our study. WT1 mutations were determined by Sanger sequencing, and expression levels were determined by real-time PCR. The Kaplan-Meier method was used to calculate overall survival (OS) and disease-free survival (DFS).<br> <span style="color:#ffffff;"><strong><span style="background-color:#008080;">&nbsp;Results:</span></strong></span> The frequency of WT1 mutations in the study population was 5.4%, and it did not affect overall survival (OS) (p=0.98), disease-free survival (DFS) (p=0.97), or complete remission (CR) rates in AML patients. The major allele of SNP rs16754 in the current study was A. No significant differences were found for OS (p=0.52), DFS (p=0.42), or complete remission rates among all SNP rs16754 genotypes. The overexpression of WT1 was observed in 83% of patients at diagnosis. No significant difference was found for OS (p=0.84), DFS (p=0.82), or complete remission rates between AML patients with high and low WT1 expression levels.<br> <span style="color:#ffffff;"><strong><span style="background-color:#008080;">&nbsp;Conclusion:</span></strong></span> The results of the current study do not support WT1 mutation, SNP rs16754, or WT1 overexpression at diagnosis, as they were found to be poor prognostic markers in AML patients.</span></span></p> AML, WT1 mutations, WT1 expression, SNP rs16754, Outcomes 109 117 http://journal.zums.ac.ir/browse.php?a_code=A-10-5548-1&slc_lang=en&sid=1 Shahrbano Rostami rostamy@yahoo.com 5200319475328460057182 5200319475328460057182 No Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Ahmad Kazemi a.kazemi32@gmail.com 5200319475328460057183 5200319475328460057183 No Dept. of Hematology, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran. Bahram Chahardouli chbahram@yahoo.com 5200319475328460057184 5200319475328460057184 No Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Saeed Mohammadi smohammadi@sina.tums.ac.ir 5200319475328460057185 5200319475328460057185 No Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Mohsen Nikbakht M-Nikbakht@sina.tums.ac.ir 5200319475328460057186 5200319475328460057186 No Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Nasrin Alizadeh alizad_n@yahoo.com 5200319475328460057187 5200319475328460057187 No Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Asadollah Mousavi a_mousavi@tums.ac.ir 5200319475328460057188 5200319475328460057188 No Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Kamran Alimoghaddam alimgh@ams.ac.ir 5200319475328460057189 5200319475328460057189 No Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Majid Teremmahi Ardestani majidardestani50@gmail.com 5200319475328460057190 5200319475328460057190 Yes Dept. of Medical Technology, School of Allied Medical Sciences, Hormozgan University of Medical Sciences, Bandar Abbas, Iran